CoreWeave: I'm Still Not Willing To Buy It

CoreWeave's Q1 2026 revenue surged 112% YoY to $2.08B and backlog reached $99.4B, but the company still posted a $740M net loss and an adjusted operating margin of only ~1%. Heavy capex of $6.8B in the quarter, FY guidance of $31-35B, and interest expense at 26% of revenue highlight rising leverage and financing risk despite strong AI-driven demand.

Analysis

The market is still rewarding CoreWeave for growth, but the business is starting to behave less like a software compounder and more like a highly levered infrastructure financier. The important second-order effect is that every incremental dollar of revenue is now being pre-committed to capex, debt service, and power/buildout intensity, which caps equity upside even if demand stays strong. In that setup, the equity becomes a duration asset on future margin normalization, while the credit stack becomes the cleaner expression of the thesis.

The competitive implication is that faster capacity scaling may actually help hyperscaler and AI infrastructure customers more than CRWV equity holders. If financing markets tighten, stronger balance sheets elsewhere can step in to capture the next wave of AI spend at better terms, while CRWV is forced to keep issuing debt or equity into a less forgiving market. That creates a months-long risk window where backlog visibility is high but monetization quality is low, and any slowdown in funding access can hit the stock well before demand rolls over.

The biggest tail risk is not a demand miss; it is a funding mismatch. A few quarters of heavy capex with thin operating margin means even small changes in rates, refinancing spreads, or customer concentration can overwhelm the P&L, and the equity could re-rate sharply if investors start treating the backlog as encumbered rather than monetizable. The contrarian view is that the consensus may be underestimating how valuable contracted revenue is in a scarcity environment, but that only matters if CRWV can convert backlog into free cash flow without permanent balance-sheet dilution.

Key Decisions for Investors

• Avoid outright long CRWV equity here; the risk/reward is poor over the next 3-6 months because upside from backlog visibility is capped by capex intensity and debt service drag.
• If expressing a bullish AI-infrastructure view, prefer a pair: long a stronger-balance-sheet beneficiary in the same AI ecosystem versus short CRWV, to isolate funding-risk underperformance rather than AI demand beta.
• Consider a tactical short CRWV into strength on rallies over the next 1-2 months, with a tight stop if management demonstrates materially improved free-cash-flow conversion or cheaper financing access.
• For hedged convexity, buy medium-dated put spreads on CRWV into any post-earnings bounce; the setup favors a slow bleed followed by sharp downside if credit spreads widen.
• Watch CRWV bond performance and refinancing news as the lead indicator; if secondary debt trades off 200-300 bps before equity weakness, that is the cleaner signal to add to the short.